Annual reportSep 2026
Sep 2026 · Shareholders meeting 8 Sep - 17th AGM on 30 Sep 2026; annual report issued, with migration and related-party resolutions.
Source: Nse
Mohini Health & Hygiene Ltd. (MHHL)
SME CapPharma stocks · SME cap · NSE
Mohini Health & Hygiene Ltd. operates in Hygiene Products, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals15 Oct 2026 · screener
Latest result01 Jun, 07:47 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
50Neutralfull bear SMA stack · SMA20 -7.6% / mo · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 18
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
MHHLD candles · FIT view-32.3%Latest close ₹29.80 on 2026-10-19
Bar
-4.8%
RSI
40
MACD hist
-0.04
52W pos
3%
2026-10-19O ₹31.30H ₹31.30L ₹29.80C ₹29.80Vol 3,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
MHHLNifty PharmaNifty 500
- MHHL
- -19.2%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -13.7 pp
Chart stats
19 Oct 2026- From 52W high
- -52.4%
- 52W range position
- 2%
- ATR (14)
- 5.0%
- Volume vs 20D
- 0.49x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹29.3 - ₹36.6
₹62.7
₹29.2 - ₹62.7
₹1.5
Latest completed session
20-session average
58.6% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED18
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -27.6% · PAT -316.7% YoY
Technical
Neutral50
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence57
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Bad · 0/100Rev -28% YoY · PAT -317% YoY · margin compression
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹71 Cr | -27.6% | -4.0% |
| EBITDA | ₹0 Cr | NDF | +100.0% |
| Operating margin | -0.4% | NDF | +280 bps |
| PAT | ₹-13 Cr | -316.7% | NDF |
| PAT margin | -18.3% | NDF | -1290 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 0.65
- EV/EBITDA
- 46.10
- Market Cap
- 57.20Cr
Profitability
- ROE
- -8.88%
- ROCE
- -3.85%
- ROA
- -11.04%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 1.00%
- EPS 5Y
- 6.00%
- Revenue 3Y
- -9.00%
- EPS 3Y
- -23.00%
Balance Sheet
- Debt/Equity
- 0.40
- Interest Coverage
- -0.75×
- Altman Z
- 2.23
- Book Value
- 48.60
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 6/5
- OCF
- 9.00 Cr
- EPS TTM
- -9.14
Shareholding
- Promoter Hold
- 64.02%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 10%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 71.0-4.1% vs prev
Net Profit
₹ CrLatest: -13.0-225.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 40.
- SMA20 falling (~8.3% over last month) — short-term momentum negative.
- RSI(14) at 40 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
7
RS percentile
Stage 4 Downtrend
1M return
-18.6%
3M return
-25.5%
6M return
-29.0%
1Y return
-51.7%
RS 1D
-2
RS 20D
-38
Sector rank
#1
Industry rank
-
Stage evidence
- Price is 19.4% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -3.1%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
184 observations
19 Oct 2026Value 58.12-4.80%
RS vs Nifty 50058
Valuation & peers
U-Score 18 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 18 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation5/30
Growth4/25
Quality0/20
Balance Sheet9/15
Cash Flow4/10
Piotroski
5/9 (+3)
Penalties
-7
Raw sum
18
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
18/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 9/15 to the score.
- Cash flow contributes 4/10 to the score.
- Valuation contributes 5/30 to the score.
Main drags
- Penalty bucket subtracts 7 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Growth is weaker at 4/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
0.7
EV/EBITDA
46.1
ROE
-8.9%
ROCE
-3.9%
FCF Yield
—
Debt/Equity
0.4
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
18
Previous: 18
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
20
20
20
18
18
18
18
18
18
18
18
18
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
14.1
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
WALPAR
SME
Walpar Nutritions Ltd.
Consumer Healthcare
match 130
64
9.9
13.9%
+78%
UNDERVALUED
KAYA
Small
Kaya Limited
Consumer Healthcare
match 115
11
—
—
—
OVERVALUED
AMRUTANJAN
Small
Amrutanjan Health Care Limited
Consumer Healthcare
match 99
52
73.4
20.0%
-113%
FAIR VALUE
AATMAJ
SME
Aatmaj Healthcare Ltd.
Pharma
match 96
13
69.1
1.4%
-4150%
OVERVALUED
ONYX
SME
Onyx Biotec Ltd.
Pharmaceuticals
match 96
15
—
-0.4%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Mohini Health & Hygiene Ltd. operates in Hygiene Products, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
57Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 20th percentile of the scored universe and 14th percentile within Pharma. Main check: results consistency is weak at 15/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
20th percentile
overall median 67 · Pharma: 14th pctile, median 70 · SME: 21st pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
30
weak · capital discipline
Results
15
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 64%.
- ▸Promoter pledge is zero.
- ▸7 years of positive FCF.
Trust risks
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at -3.8%.
- ▸ROE is low at -8.9%.
- ▸ROCE trend is -17.2%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Mohini Health & Hygiene Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Credit rating
Credit Rating- Revision 5 Sep - Ind-Ra downgraded MHHL bank loans worth ₹760.51 million to IND BB- and IND A4+.
Source: Nse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.